Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bromodomain Drug Discovery – the Past, the Present, and the Future

5 Oct 2018

Abstract excerpt

With the bromodomain (BRD) inhibitor JQ1, a remarkable success story of BRD4 as a novel drug target has been set off that yielded many anti-cancer drugs that are now in clinical trials. But not all of the great prospects of BRDs as drug targets may become true. First evaluations of ongoing clinical trials revealed that treatment with BET-inhibitors can be accompanied with significant toxic side effects and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30289209
DOI: 10.1002/tcr.201800074

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bromodomain Drug Discovery – the Past, the Present, and the FuturePMID 30289209Read ↗

Targeting BET Bromodomains for Cancer TreatmentSemantic proximity Read ↗

Design and Synthesis of a Highly Selective and In Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of ProteinsSemantic proximity Read ↗

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseasesSemantic proximity Read ↗

Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseasesSemantic proximity Read ↗

Targeting BET bromodomain proteins in cancer: The example of lymphomasSemantic proximity Read ↗

Targeting BET Bromodomains in CancerSemantic proximity Read ↗

Precision Targeting of BET Proteins - Navigating Disease Pathways, Inhibitor Insights, and Shaping Therapeutic Frontiers: A Comprehensive ReviewSemantic proximity Read ↗

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous ProteinsSemantic proximity Read ↗

Domain-selective targeting of BET proteins in cancer and immunological diseasesSemantic proximity Read ↗

Bromodomains as therapeutic targets in cancerSemantic proximity Read ↗

Clinical progress and pharmacology of small molecule bromodomain inhibitorsSemantic proximity Read ↗

Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.